Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Government ‘confident’ people will get ‘bivalent’ jab in booster programme

The comments come after it emerged that current stock would cover only half the population eligible for the booster jab.

The Independent UK

Who is eligible to get a Covid booster jab this autumn

Some people will be offered a Moderna jab and others the Pfizer vaccine

Wales Online

Pfizer CEO tests positive for Covid

Albert Bourla has already received four doses of the Pfizer-BioNTech vaccine

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer CEO tests positive for COVID-19, has mild symptoms

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms

The Independent UK

Who can get a Covid vaccine booster in the UK?

The autumn booster program for Covid vaccinations will begin shortly. Over 50s, carers, frontline health workers and those at clinical risk will be inited to get a booster jab.

Edinburgh Live

'Next generation' Covid vaccine that targets Omicron to be rolled out in Autumn

The groundbreaking Moderna jabs, which target both the Omicron variant and the original strain of the killer virus, will be rolled out in a bid to avoid a winter NHS nightmare

Daily Mirror

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Benzinga

Covid vaccine booster to be made available to more people in coming weeks

There are several ways you can book an appointments for yours

Dublin Live

A vaccine for Lyme disease is in its final clinical trial

There isn't currently a Lyme disease vaccine on the U.S. market. Researchers are hoping to change that.

WEKU

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Pfizer's Perth employees strike over pay

Pharmaceutical giant Pfizer is facing calls to improve its pay offer to manufacturing employees in Perth, who have walked off the job.

AAP

Trial seeks to develop first Lyme disease vaccine in 2 decades

The only Lyme disease vaccine previously marketed in the U.S. was discontinued in 2002.

Axios

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Major test of first possible Lyme vaccine in 20 years begins

Researchers are seeking thousands of volunteers in the U.S. and Europe to test the first potential vaccine against Lyme disease in 20 years

Investors Business Daily

Stock Market Rally Fades; These Energy, Health Care Stocks Break Out

Major indexes jumped at the week's opening, they pared most gains.

Investors Business Daily

Stock Market Gains On Tax, Climate, Health Care Bill; 6 Breakouts Amid Mixed Week Of Earnings

The stock market gained on tax, climate health care bill. The latest week or earnings arrived with lackluster results.

Investors Business Daily

Why Pfizer's $5.4 Billion GBT Takeover Is 'Mutually Beneficial'

Pfizer inked a $5.4 billion deal Monday to buy Global Blood Therapeutics, confirming rumors that sent GBT stock skyrocketing last week.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

BioNTech reports strong first half, expects demand to grow

BioNTech, which teamed with Pfizer to develop the first widely used COVID-19 vaccine, has reported higher revenue and net profit in the first half of the year

Benzinga

Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8

CNBC Celsius Withdraws Motion To Rehire CFO

Reuters

Climate change puts Lyme disease in focus for France's Valneva after COVID blow

With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot.

Investors Business Daily

Stock Market Ends Upbeat Week With Mixed Results On Hot Job Numbers

The stock market traded mixed on Friday on hot job numbers, closing out the week with gains. AMC popped on earnings beat.

Investors Business Daily

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Rumors that Pfizer is in "advanced talks" to acquire Global Blood Therapeutics for about $5 billion sent GBT stock flying Friday.

Investors Business Daily

Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug

Alnylam stock cooled Friday as one expert argued the company will have to run a second study of its cardiomyopathy drug to gain traction.

Axios

Over 1 million courses of Paxlovid prescribed in one month for first time

There were 1.26 million courses dispensed last month, a 37% increase when compared to June numbers.

1 … 37 38 39 40

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.